[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ndonovo Therapeutics Inc (ENDV)

Ndonovo Therapeutics Inc (ENDV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Financial Summary for [[ item.sessionDateDisplayLong ]]
Endonovo Therapeutics, Inc. is a biotechnology company which is engaged in developing a bioelectronic approach to regenerative medicine. The company's Immunotronics(TM) platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation and necrosis, and the promotion of regeneration. Endonovo's Cytotronics(TM) platform provides method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields for tissue engineering and cell therapies. Endonovo Therapeutics, Inc. is headquartered in Woodland Hills, California.

Fiscal Year End Date: 12/31

(Values in U.S. Thousands) Mar, 2026 Dec, 2025 Sep, 2025 Mar, 2025 Sep, 2024
Sales 0 0 0 0 0
Sales Growth unch unch unch unch -100.00%
Net Income -590 -540 -540 -530 -700
Net Income Growth -9.26% unch -1.89% +24.29% +51.05%
(Values in U.S. Thousands) Mar, 2026 Dec, 2025 Sep, 2025 Mar, 2025 Sep, 2024
Total Assets 640 820 1,010 1,200 1,280
Total Assets Growth -21.95% -18.81% -15.83% -6.25% -11.72%
Total Liabilities 24,750 23,780 23,220 25,570 33,460
Total Liabilities Growth +4.08% +2.41% -9.19% -23.58% +58.88%
(Values in U.S. Thousands) Mar, 2026 Dec, 2025 Sep, 2025 Mar, 2025 Sep, 2024
Operating Cash Flow 120 -400 -340 -170 -680
Operating Cash Flow Growth +130.00% -17.65% -100.00% +75.00% -51.11%
Net Cash Flow 0 0 30 10 -90
Change in Net Cash Flow unch -100.00% +200.00% +111.11% -50.00%
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.